This message was sent by the FDA Office of Women's Health. www.fda.gov/womens
Antiviral Drugs Advisory Committee Meeting
Date and Time: May 11, 2012 from 8:00 a.m. to 5:00 p.m.
Location: Doubletree by Hilton Hotel
The Ballrooms
8727 Colesville Road
Silver Spring, MD
On May 11, 2012, the committee will discuss a new drug application (NDA) 203-100, for a fixed dose combination tablet of elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate, submitted by Gilead Sciences, Inc. The application proposes an indication for the treatment of HIV-1 infection in adults who are antiretroviral naïve or have no known substitutions associated with resistance to the individual components.
View the Meeting Announcement:
http://www.fda.gov/AdvisoryCommittees/Calendar/ucm297233.htm
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
